We aim to meet your unique requirements for experimental design and analysis output, while exceeding service expectations with our "white-gloved" approach.
See how combination drug screens helped discover agents resulting in enhanced efficacy in pre-clinical models of multiple myeloma.
'ATL313, A Potent, and Selective A2A Agonist as a Novel Drug Candidate for the Treatment of Multiple Myeloma'
Perform drug screens 200 cell lines from our OncoSignature™ library grown in 3D spheroids.
Rapidly screen agents on their capacity of inducing cell apoptosis in a broad panel of cell types.
Enhancer Screening
Look for selective pipeline candidate enhancers, approved therapeutics, emerging targeted agents and molecular probes.
Pairwise Screening
Identify novel synergistic combinations of pipeline candidates, emerging targeted agents, and approved drugs.
